Catalyst Pharmaceuticals (DB:CN2) - Stock Price, News & Analysis

CN2 Stock Overview

Catalyst Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase comercial centrada en el desarrollo y la comercialización de terapias para personas con enfermedades neuromusculares y neurológicas raras, debilitantes y crónicas en Estados Unidos.

About the company

CN2 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Cotiza un 80.6% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 25.77%

Los analistas coinciden en que el precio de las acciones subirá un 63%

Risk Analysis

Alto nivel de ganancias no monetarias

Venta significativa de accionistas con acceso a información confidencial en los últimos 3 meses

Los márgenes de beneficio (17.8%) son inferiores a los del año pasado (34.9%)

Los accionistas se han diluido en el último año

Catalyst Pharmaceuticals, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Dermapharm Holding

XTRA:DMP

€1.7b

Gerresheimer

XTRA:GXI

€3.6b

Bonesupport Holding

OM:BONEX

kr15.1b

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Pharmaceuticals
Historical stock prices
Current Share Price	US$13.76
52 Week High	US$16.58
52 Week Low	US$10.43
Beta	0.88
1 Month Change	-8.11%
3 Month Change	5.36%
1 Year Change	-10.01%
3 Year Change	273.61%
5 Year Change	181.91%
Change since IPO	1,530.33%

Recent updates

Shareholder Returns

	CN2	DE Biotechs	DE Market
7D	-7.8%	4.5%	-1.3%
1Y	-10.0%	-13.9%	4.1%

Rentabilidad frente al sector: CN2 obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del 25.8%.

Rentabilidad vs. Mercado: CN2 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.5% el año pasado.

Price Volatility

Is CN2's price volatile compared to industry and market?
CN2 volatility
CN2 Average Weekly Movement	6.6%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.7%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: CN2 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CN2 (7%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
2002	167	Rich Daly	https://www.catalystpharma.com

Catalyst Pharmaceuticals, Inc, empresa biofarmacéutica en fase comercial, se centra en el desarrollo y la comercialización de terapias para personas con enfermedades neuromusculares y neurológicas raras, debilitantes y crónicas en Estados Unidos. Ofrece Firdapse, comprimidos de fosfato de amifampridina para el tratamiento de pacientes con síndrome miasténico de Lambert-Eaton (LEMS); y Ruzurgi para el tratamiento de pacientes pediátricos con LEMS. La empresa desarrolla Firdapse para el tratamiento de la miastenia gravis positiva a anticuerpos MuSK y la atrofia muscular espinal tipo.

Catalyst Pharmaceuticals, Inc. Fundamentals Summary

How do Catalyst Pharmaceuticals's earnings and revenue compare to its market cap?
CN2 fundamental statistics
Market cap	€1.65b
Earnings (TTM)	€65.90m
Revenue (TTM)	€367.46m

25.0x

P/E Ratio

4.5x

P/S Ratio

Is CN2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CN2 income statement (TTM)
Revenue	US$398.20m
Cost of Revenue	US$145.12m
Gross Profit	US$253.09m
Other Expenses	US$181.68m
Earnings	US$71.41m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.61
Gross Margin	63.56%
Net Profit Margin	17.93%
Debt/Equity Ratio	0%

How did CN2 perform over the long term?

See historical performance and comparison

CN2 Stock Overview

Rewards

Risk Analysis

Catalyst Pharmaceuticals, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:DMP

€1.7b

XTRA:GXI

€3.6b

OM:BONEX

kr15.1b

Price History & Performance

Recent News & Updates

Insider recently sold €380k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.67 (vs US$0.80 in FY 2022)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Recent updates

Insider recently sold €380k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.67 (vs US$0.80 in FY 2022)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Investor sentiment improves as stock rises 17%

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold €528k worth of stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.22 profit in 3Q 2022)

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

New minor risk - Share price stability

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Investor sentiment deteriorates as stock falls 28%

First quarter 2023 earnings released: EPS: US$0.28 (vs US$0.13 in 1Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Full year 2022 earnings released: EPS: US$0.80 (vs US$0.38 in FY 2021)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Director recently sold €321k worth of stock

Third quarter 2022 earnings released: EPS: US$0.22 (vs US$0.10 in 3Q 2021)

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric Patients

Chief Accounting Officer recently sold €734k worth of stock

Co-Founder recently sold €16m worth of stock

Investor sentiment improved over the past week

Chief Accounting Officer recently sold €970k worth of stock

Chief Commercial Officer recently sold €198k worth of stock

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.12 in 2Q 2021)

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Sep 19, 2022

Catalyst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.074 in 1Q 2021)

Catalyst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Catalyst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 16, 2022

Catalyst Pharmaceuticals, Inc. Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Catalyst Pharmaceuticals, Inc. Further Strengthens FIRDAPSE® U.S. Patent Portfolio